Literature DB >> 21547513

Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes.

Berna Dilbaz1, Enis Ozkaya, Mehmet Cinar, Evrim Cakir, Serdar Dilbaz.   

Abstract

The aim of this article was to evaluate the clinical, endocrine, and cardiovascular disease risk profile differences among main polycystic ovary syndrome (PCOS) phenotypes. One hundred and thirty-nine consecutive women were included in the study. Body mass index (BMI), serum follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone, estradiol, testosterone, dehydroepiandrosterone sulfate, fasting glucose, low density lipoprotein (LDL-C), total cholesterol, high density lipoprotein (HDL-C) high sensitive CRP, c-peptide, insulin, insulin sensitivity and carotid intima thickness were compared among different phenotype groups of PCOS: Group 1-PCO (polycystic ovaries)-anovulation (n = 34), Group 2-Hyperandrogenemia (HA)-anovulation (n = 30), Group 3-HA-PCO (n = 32), and Group 4-HA-PCO-anovulation (n = 43). Statistically significant differences among the different phenotype groups in terms of waist hip ratio, total cholesterol, LH, estradiol, fasting glucose, progesterone, free testosterone, and carotid intima media thickness were observed. The lowest mean CIMT was observed in Group 3, and the highest fasting glucose levels were in Group 4, while the lowest mean free testesterone was measured in Group 1. BMI, LDL-C, and total cholesterol showed significant positive correlations with CIMT (r = 0.411, P = 0.001; r = 0.258, P = 0.006; r = 0.199, P = 0.033). The lowest LDL-C, total cholesterol, and BMI were found in Group 3, but differences were not statistically significant. High-sensitive CRP levels were similar among the groups (P = 0.103). Group 3 PCOS with PCO and hyperandrogenemia phenotype has lower cardiovascular disease risk compared to other phenotypes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547513     DOI: 10.1007/s12020-011-9437-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  22 in total

1.  Cardiovascular risk factors in polycystic ovary syndrome.

Authors:  A Karaer; S Cavkaytar; I Mert; U Buyukkagnici; S Batioglu
Journal:  J Obstet Gynaecol       Date:  2010-05       Impact factor: 1.246

2.  Variation in metabolic and cardiovascular risk in women with different polycystic ovary syndrome phenotypes.

Authors:  Denusa Wiltgen; Poli Mara Spritzer
Journal:  Fertil Steril       Date:  2010-03-24       Impact factor: 7.329

3.  Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study.

Authors:  J C Lovejoy; G A Bray; M O Bourgeois; R Macchiavelli; J C Rood; C Greeson; C Partington
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

4.  Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes.

Authors:  Ettore Guastella; Rosa Alba Longo; Enrico Carmina
Journal:  Fertil Steril       Date:  2010-03-19       Impact factor: 7.329

Review 5.  Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome.

Authors:  Charikleia D Christakou; Evanthia Diamanti-Kandarakis
Journal:  Womens Health (Lond)       Date:  2008-11

Review 6.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

7.  Do hyperandrogenic women with normal menses have polycystic ovary syndrome?

Authors:  E Carmina; R A Lobo
Journal:  Fertil Steril       Date:  1999-02       Impact factor: 7.329

8.  Polycystic ovaries and infertility: Our experience.

Authors:  Lavanya Rajashekar; Deepika Krishna; Madhuri Patil
Journal:  J Hum Reprod Sci       Date:  2008-07

9.  Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.

Authors:  Rose C Christian; Daniel A Dumesic; Thomas Behrenbeck; Ann L Oberg; Patrick F Sheedy; Lorraine A Fitzpatrick
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome.

Authors:  Manuel Luque-Ramírez; Covadonga Mendieta-Azcona; Francisco Alvarez-Blasco; Héctor F Escobar-Morreale
Journal:  Hum Reprod       Date:  2007-10-11       Impact factor: 6.918

View more
  10 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

2.  Insulin resistance and acne: a new risk factor for men?

Authors:  Michela Del Prete; Maria Chiara Mauriello; Antongiulio Faggiano; Carolina Di Somma; Giuseppe Monfrecola; Gabriella Fabbrocini; Annamaria Colao
Journal:  Endocrine       Date:  2012-03-25       Impact factor: 3.633

3.  Nesfatin-1 and other hormone alterations in polycystic ovary syndrome.

Authors:  Rulin Deniz; Bilgin Gurates; Suleyman Aydin; Husnu Celik; Ibrahim Sahin; Yakup Baykus; Zekiye Catak; Aziz Aksoy; Cihan Citil; Sami Gungor
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

4.  Metabolic syndrome and the risk of cardiovascular complications in young patients with different phenotypes of polycystic ovary syndrome.

Authors:  Anna Krentowska; Agnieszka Łebkowska; Małgorzata Jacewicz-Święcka; Justyna Hryniewicka; Monika Leśniewska; Agnieszka Adamska; Irina Kowalska
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

Review 5.  What do we know about metabolic syndrome in adolescents with PCOS?

Authors:  Derya Akdağ Cırık; Berna Dilbaz
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-03-01

6.  Gestational Diabetes Mellitus and Metabolic Disorder Among the Different Phenotypes of Polycystic Ovary Syndrome.

Authors:  Mahnaz Ashrafi; Fatemeh Sheikhan; Arezoo Arabipoor; Nicole Rouhana; Roya Hosseini; Zahra Zolfaghari
Journal:  Oman Med J       Date:  2017-05

7.  Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome.

Authors:  Ling Gao; Jia-Tian Cao; Yan Liang; Yi-Chao Zhao; Xian-Hua Lin; Xiao-Cui Li; Ya-Jing Tan; Jing-Yi Li; Cheng-Liang Zhou; Hai-Yan Xu; Jian-Zhong Sheng; He-Feng Huang
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

8.  Importance of lipid accumulation product index as a marker of CVD risk in PCOS women.

Authors:  Joelma Ximenes Prado Teixeira Nascimento; Maria Bethânia da Costa Chein; Rosângela Maria Lopes de Sousa; Alexsandro dos Santos Ferreira; Paula Andrea Navarro; Luciane Maria Oliveira Brito
Journal:  Lipids Health Dis       Date:  2015-06-24       Impact factor: 3.876

9.  Effect of body weight on serum homocysteine level in patients with polycystic ovarian syndrome: A case control study.

Authors:  Ali I Al-Gareeb; Wafaa Salah Abd Al-Amieer; Hayder M Alkuraishy; Thabat J Al-Mayahi
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-02

Review 10.  MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease.

Authors:  Lina Schiffer; Punith Kempegowda; Wiebke Arlt; Michael W O'Reilly
Journal:  Eur J Endocrinol       Date:  2017-05-31       Impact factor: 6.664

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.